IBMX (28822-58-4) is a pan-specific inhibitor of phosphodiesterases (IC50=2-50 μM). Inhibition of PDEs leads to increased concentration of intracellular cAMP which activates PKA.2IBMX does not inhibit PDE8 or PDE9.3Weak adenosine receptor antagonist.4
White Needles with Yellow Cast
phosphodiesterase inhibitor
A nonspecific inhibitor of phosphodiesterases
3-Isobutyl-1-methylxanthine is used in inhibition of phenylephrine-induced release of 5-hydroxytryptamine from neuroendocrine epithelial cells of the airway mucosa (IC50 = 1.3 uM). Also inhibits ion channels in the neuromuscular junction, GH3 cells, and vascular smooth muscle cells. Inhibits the growth of carcinoma cells both in vivo and in vitro in mice.
ChEBI: 3-isobutyl-1-methyl-9H-xanthine is a 3-isobutyl-1-methylxanthine. It is functionally related to a 9H-xanthine. It is a tautomer of a 3-isobutyl-1-methyl-7H-xanthine.
3-isobutyl-1-methylxanthine/IBMX is a non-selective, non-specific inhibitor of cAMP and cGMP phosphodiesterases. IBMX can induce melanogenesis, and can be used as a positive control in melanogenesis research. In oocyte research, IBMX assists in maintaining the germinal vesicle (GV) arrest of prophase I oocytes.
Phosphodiesterase inhibitor (IC 50 values are 13, 18, 19, 32 and 50 μ M for PDE4, PDE3, PDE1, PDE5 and PDE2 respectively). Suppresses α -adrenoceptor-mediated 5-HT release from neuroendocrine epithelial cells (IC 50 = 1.3 μ M).
The increase in cAMP level as a result of phosphodiesterase inhibition by IBMX activates PKA, leading to decreased proliferation, increased differentiation, and induction of apoptosis. IBMX inhibits phenylephrine-induced release of 5-hydroxytryptamine from neuroendocrine epithelial cells of the airway mucosa (IC50: 1.3 μM). IBMX also serves as an adenosine receptor antagonist. IBMX has been shown to inhibit ion channels in the neuromuscular junction, GH3 cells, and vascular smooth muscle cells. IBMX induces calcium release from intracellular stores in sensory neurons.
Recrystallise it from aqueous EtOH. [Beilstein 26
3-isobutyl-1-methylxanthine is a nonselective inhibitor of cAMP and cGMP phosphodiesterases. Research studies show that IBMX inhibits many members of the PDE family, with the exceptions of PDE8A, PDE8B, and PDE9. Treatment of cells with IBMX promotes accumulation of cAMP and cGMP, which leads to activation of cyclic-nucleotide-regulated protein kinases. Additional research indicates that IBMX can promote neuronal progenitor cell maturation in vitro.
[1] J A BEAVO. Effects of xanthine derivatives on lipolysis and on adenosine 3’,5’-monophosphate phosphodiesterase activity.[J]. Molecular Pharmacology, 1970, 6 6: 597-603.
[2] CLAUDIA TOMES Silvia M Silvia Rossi. Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity[J]. Cellular signalling, 1993, 5 5: Pages 615-621. DOI:
10.1016/0898-6568(93)90056-r[3] SCOTT H SODERLING Joseph A B. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions[J]. Current Opinion in Cell Biology, 2000, 12 2: Pages 174-179. DOI:
10.1016/s0955-0674(99)00073-3[4] J W DALY D U K A Jacobson. Adenosine receptors: development of selective agonists and antagonists.[J]. Progress in clinical and biological research, 1987, 230: 41-63.
